Internetiühendust pole — kuvatakse lehe salvestatud versioon.

GSK plc

USUSD
← Aktsiafiltri juurde
US:GLAXFLSE:GSKXETRA:GS71

GSK plc (US:GLAXF) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 2. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.

Ettevõtte kohta

Veebileht
gsk.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Peakontor
LONDON, United Kingdom
Tegevjuht
Emma Walmsley
Töötajad
97 921
Asutatud
2000
Ringluses olevad aktsiad
4.01 mld seisuga 2025-12-31
1 aasta: +0.03% · 3 aastat: +0.10% · 5 aastat: −19.9% (aktsiate splitte arvestamata)
KuupäevAktsiadMuutus
31.12.20254.32 mld+0.03%olulisi muudatusi pole
31.12.20244.31 mld+0.05%olulisi muudatusi pole
31.12.20234.31 mld+0.02%olulisi muudatusi pole
31.12.20224.31 mld−20.0%tagasiost
31.12.20215.39 mld+0.03%olulisi muudatusi pole
31.12.20205.39 mld+0.04%olulisi muudatusi pole
31.12.20195.38 mld+0.08%olulisi muudatusi pole
31.12.20185.38 mld+0.1%emissioon (lahjendamine)
31.12.20175.37 mld
Aktsiate arv ettevõtte aruannete järgi. Spliti tuvastatakse aktsiate arvu hüppe järgi täisarv korda.
Vabalt kaubeldavad aktsiad
3.88 mld
Turukapitalisatsioon
96.13 mld USD
Siseringi isikud
1.75%
Institutsionaalsed investorid
49.09%
Tegevusala (SIC)
Pharmaceutical Preparations
Õiguslik vorm
B6ES
ISIN
GB0009252882
LEI
5493000HZTVUYLO1D793
Väljamaksesuhe
55.3%
FCF
5.33 mld GBP
50%
Võlg
18.2 mld GBP
2.6 a FCF
Dividendistaaž
39 a
Kirjeldus

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Börsid ja tikkerid

BörsTikkerValuutaHindTüüp
US USA StocksGLAXFUSD23.55 +3.43%tavalised aktsiad
LSE London Stock ExchangeGSKGBP17.75 +0.91%tavalised aktsiad

Hind 3 kuu jooksul

3M1Y3Y5Y
tõususepäev langusepäev dividendi ex-kuupäev väljamakse kuupäevViige kursor / puudutage päeva — avamis-, sulgemis-, kõrgeim ja madalaim hind

Dividendid

Viimased 12 kuud, US:GLAXF: 0.52 GBP (3 väljam.)

st_dt_pays_quarterly st_dt_12m st_dt_forecast st_dt_years

Ex-kuupäevVäljamakseSumma%TüüpTikker
2026-08-142026-10-080.1700 GBP1.0/≈3.8 %kord kvartalisUS:GLAXF
2026-05-152026-07-090.1700 GBP1.0/≈3.8 %kord kvartalisUS:GLAXF
2026-02-202026-04-090.1800 GBP1.0/≈4.0 %kord kvartalisUS:GLAXF

News this week

Ettevõtte veebisaidilt uudiseid veel pole.

reklaam

Suurimad omanikud

OmanikOsalusAktsiadAruande kuupäev
GSK Plc≈6.7%270.88 mln2026-08-31
BlackRock Advisors (UK)…≈5.67%229.13 mln2026-02-25
Dodge & Cox≈2.2%88.82 mln2026-06-24
Dodge & Cox Funds-Dodge…1.57%63.37 mln2026-06-30
GlaxoSmithKline Plc ESOP≈1.56%62.88 mln2025-12-31
VANGUARD STAR FUNDS-Vang…1.45%58.47 mln2026-04-30
VANGUARD SPECIALIZED FUN…1.09%44.05 mln2026-07-31
VANGUARD TAX-MANAGED FUN…0.96%39.01 mln2026-06-30
iShares Trust-iShares Co…0.74%30.06 mln2026-07-31
MFS Series Trust XVII-MF…0.42%16.83 mln2026-06-30
Fidelity Concord Street…0.39%15.77 mln2026-07-31
iShares Trust-iShares MS…0.35%14.35 mln2026-08-31
HARTFORD MUTUAL FUNDS IN…0.29%11.67 mln2026-07-31
Bridge Builder Trust-Bri…0.28%11.23 mln2026-06-30
Aristotle Capital Manage…0.07%2.63 mln2026-06-30
Walmsley (Emma Natasha)≈0.06%2.43 mln2025-12-31
Pacer Advisors, Inc.0.06%2.54 mln2026-06-30
Miels (Luke)≈0.04%1.48 mln2026-07-09
Redfern (David S)≈0.03%1.1 mln2026-09-09
Thomson (Phil C)≈0.01%531 6582026-09-09
Brown (Julie)≈0.01%413 4952026-09-09
Simard (Regis)≈0.01%334 6802026-09-09
Paradigm Asset Managemen…0%66 2002026-06-30
Generali Investments Cee…0%34 1052026-06-30

Järelevalveasutuse sündmused

KuupäevJärelevalveasutusSündmusÜksikasjad
2026-10-02ESMAоновлення даних інструментаISIN, майданчик HAND